Approval

Adcomfo Wins European Approval

The European Commission approved Adcomfo, a biosimilar to Xolair, for eligible patients with allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria. A 600-patient urticaria study met its primary endpoint for equivalent efficacy; ADVANZ PHARMA holds European commercialization rights. The approval follows UK authorization in March 2026, while Amneal's U.S. application remains under FDA review.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call